Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Abacavir

R H Foster1, D Faulds

  • 1Adis International Limited, Auckland, New Zealand.

Drugs
|May 20, 1998
PubMed
Summary
This summary is machine-generated.

Abacavir, an effective HIV treatment, shows slow resistance development and improves viral load and CD4+ counts. Common side effects include rash and fatigue, with hypersensitivity reactions in 2-3% of patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

CNS drugs·2013
Same author

Mycophenolate mofetil: a review of its use in the management of solid organ transplantation.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Tetravalent human-rhesus reassortant rotavirus vaccine: a review of its immunogenicity, tolerability and protective efficacy against paediatric rotavirus gastroenteritis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Alitretinoin.

American journal of clinical dermatology·2001
Same author

Olanzapine: an updated review of its use in the management of schizophrenia.

Drugs·2001
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Virology
  • Immunology

Background:

  • Abacavir is a nucleoside analogue reverse transcriptase inhibitor.
  • It demonstrates in vitro potency against clinical HIV isolates comparable to zidovudine.
  • Resistance to abacavir develops slowly, with specific cross-resistance patterns observed.

Purpose of the Study:

  • To evaluate the efficacy and safety of abacavir in HIV treatment.
  • To assess abacavir's pharmacokinetic properties, including oral bioavailability and CNS penetration.
  • To determine the long-term effectiveness and adverse event profile of abacavir-based therapies.

Main Methods:

  • In vitro susceptibility testing against HIV isolates.
  • Animal studies to assess oral bioavailability and CNS penetration.

Related Experiment Videos

  • Phase I/II clinical trials evaluating abacavir alone and in combination with other anti-HIV agents.

    • Main Results:

    • Abacavir effectively decreased viral load and increased CD4+ cell counts in HIV-infected patients.
    • Therapeutic benefits were sustained for at least 48 weeks.
    • Common adverse events included headache, rash, and fatigue; hypersensitivity reactions occurred in 2-3% of patients.

    Conclusions:

    • Abacavir is an effective anti-HIV agent with sustained efficacy.
    • Its pharmacokinetic profile supports its use in HIV treatment regimens.
    • While generally well-tolerated, careful monitoring for hypersensitivity reactions is necessary.